SCHEMBL3700484

SCHEMBL3700484

CC1(C)Oc2ccc(Nc3nc(N4CCC(CO)(CNC(=O)O)CC4)c4occc4n3)cc2NC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 16/20 0.53
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AURKA O14965 1/20 0.37
JAK2 O60674 1/20 0.37
ROCK2 O75116 1/20 0.37
STK16 O75716 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
INSR P06213 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
RET P07949 1/20 0.37
IGF1R P08069 1/20 0.37
PDGFRB P09619 1/20 0.37
SRC P12931 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
MST1 P26927 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3706051 0.96 SYK (0.55) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3708862 0.94 SYK (0.53) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3700773 0.92 SYK (0.55) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3706865 0.92 SYK (0.51) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3706242 0.90 SYK (0.56) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL7602655 0.90 SYK (0.59) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3708042 0.89 SYK (0.54) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3701230 0.88 SYK (0.49) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3702373 0.87 SYK (0.58) SYKKDM4EALDH1A1SMN1; SMN2AURKA
SCHEMBL3705242 0.87 SYK (0.59) SYKKDM4EALDH1A1SMN1; SMN2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885KDM4E 3815/4885ALDH1A1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.